Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD. J of Skin [Internet]. 2026 Mar. 10 [cited 2026 Apr. 30];10(2):s731. Available from: https://skin.dermsquared.com/skin/article/view/4038